​

Sonnet BioTherapeutics (SONN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SONN Stock Rating

Sonnet BioTherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

SONN Price Target Upside V Benchmarks

TypeNameUpside
StockSonnet BioTherapeutics-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.26$1.26$1.26
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25-1---1
Jun, 25-1---1
May, 25-1---1
Apr, 25-1---1
Mar, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 19, 2023Chardan CapitalBuyBuyhold
Sep 15, 2021BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-2K $-1K $-900 $-600 $-300 $0 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$-1.20K$-145.12$-11.35$-3.95--
Avg Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
High Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
Low Forecast$-1.18K$-166.18$-12.88$-3.42$-98.56$-96.80
Surprise %2.33%-12.67%-11.88%15.50%--

Revenue Forecast

$0 $200K $400K $600K $800K $1M Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$349.94K$147.81K$18.63K$1.00M--
Avg Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
High Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
Low Forecast$400.00K$83.33K$50.00K$10.58K$6.01K$3.41K
Surprise %-12.51%77.37%-62.75%9352.69%--

Net Income Forecast

$-2B $-1B $-900M $-600M $-300M $0 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27
Reported$-29.77M$-18.83M$-7.44M$-16.11M--
Avg Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
High Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
Low Forecast$-1.22B$-108.89M$-8.44M$-2.24M$-64.58M$-63.43M
Surprise %-97.56%-82.70%-11.88%619.02%--

SONN Forecast FAQ

Is Sonnet BioTherapeutics stock a buy?

Sonnet BioTherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sonnet BioTherapeutics is a favorable investment for most analysts.

What is Sonnet BioTherapeutics's price target?

Sonnet BioTherapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.26.

How does Sonnet BioTherapeutics stock forecast compare to its benchmarks?

Sonnet BioTherapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sonnet BioTherapeutics over the past three months?

  • July 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Sonnet BioTherapeutics’s EPS forecast?

Sonnet BioTherapeutics's average annual EPS forecast for its fiscal year ending in September 2026 is $-98.56, marking a 2395.19% increase from the reported $-3.95 in 2025. Estimates for the following years are.

What is Sonnet BioTherapeutics’s revenue forecast?

Sonnet BioTherapeutics's average annual revenue forecast for its fiscal year ending in September 2026 is $6.01K, reflecting a -99.40% decrease from the reported $1M in 2025. The forecast for.

What is Sonnet BioTherapeutics’s net income forecast?

Sonnet BioTherapeutics's net income forecast for the fiscal year ending in September 2026 stands at $-64.581M, representing an 300.80% increase from the reported $-16.113M in 2025. Projections indicate .